Top

Published in:

Open Access 01-12-2023 | Colonoscopy | Research

Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD)

Authors: Lydia Guittet, Valérie Quipourt, Thomas Aparicio, Elisabeth Carola, Jean-François Seitz , Elena Paillaud, Astrid Lievre, Rabia Boulahssass, Carole Vitellius, Leila Bengrine, Florence Canoui-Poitrine, Sylvain Manfredi

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

We have done a systematic literature review about CRC Screening over 75 years old in order to update knowledge and make recommendations.

Methods

PUBMED database was searched in October 2021 for articles published on CRC screening in the elderly, and generated 249 articles. Further searches were made to find articles on the acceptability, efficacy, and harms of screening in this population, together with the state of international guidelines.

Results

Most benefit-risk data on CRC screening in the over 75 s derived from simulation studies. Most guidelines recommend stopping cancer screening at the age of 75. In private health systems, extension of screening up to 80–85 years is, based on the life expectancy and the history of screening. Screening remains effective in populations without comorbidity given their better life-expectancy. Serious adverse events of colonoscopy increase with age and can outweigh the benefit of screening. The great majority of reviews concluded that screening between 75 and 85 years must be decided case by case.

Conclusion

The current literature does not allow Evidence-Based Medicine propositions for mass screening above 75 years old. As some subjects over 75 years may benefit from CRC screening, we discussed ways to introduce CRC screening in France in the 75–80 age group.

IRB

An institutional review board composed of members of the 2 learned societies (SOFOG and FFCD) defined the issues of interest, followed the evolution of the work and reviewed and validated the report.

Ferlay J, Colombet M, Soerjomataram I, et al. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries and 25 Major Cancers in 2018. Eur J Cancer. 2018;103:356–87. https://doi.org/10.1016/j.ejca.2018.07.005.CrossRef

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. Eur J Cancer Oxf Engl 1990. 2013;49(6):1374–403. https://doi.org/10.1016/j.ejca.2012.12.027.CrossRef

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. https://doi.org/10.1136/gutjnl-2015-310912.CrossRef

Defossez G, Le Guyader§Peyrou S, Uhry Z. et al. Estimations Nationales de l’incidence et de La Mortalité Par Cancer En France Métropolitaine Entre 1990 et 2018. Volume 1 – Tumeurs Solides; Santé Publique France: Saint-Maurice, France, 2019; p 372.

Cottet V, Jooste V, Bouvier A-M, Michiels C, Faivre J, Bonithon-Kopp C. Time Trends in First-Diagnosis Rates of Colorectal Adenomas: A 24-Year Population-Based Study. Aliment Pharmacol Ther. 2008;27(10):950–9. https://doi.org/10.1111/j.1365-2036.2008.03675.x.CrossRef

Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the Genomic Age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9. https://doi.org/10.2471/blt.07.050112.CrossRef

Faivre J, Bossard N, Jooste V, et al. Trends in Net Survival from Colon Cancer in Six European Latin Countries: Results from the SUDCAN Population-Based Study. Eur J Cancer Prev. 2017;26:S40–7. https://doi.org/10.1097/CEJ.0000000000000293.CrossRef

Lepage, C.; Bossard, N.; Dejardin, O.; Carmona-Garcia, M. C.; Manfredi, S.; Faivre, J.; GRELL EUROCARE-5 Working Group. Trends in Net Survival from Rectal Cancer in Six European Latin Countries: Results from the SUDCAN Population-Based Study. Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. ECP 2017, 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study, S48–S55. https://doi.org/10.1097/CEJ.0000000000000305.

Council of the European Union. Council Recommendation of 2 December 2003 on Cancer Screening (2003/878/EC) 878. 2003.

10.

Smith RA, Andrews K, Brooks D, et al. Cancer Screening in the United States, 2016: A Review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening. CA Cancer J Clin. 2016;66(2):96–114. https://doi.org/10.3322/caac.21336.CrossRef

11.

Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal Cancer Population Screening Programs Worldwide in 2016: An Update. World J Gastroenterol. 2017;23(20):3632–42. https://doi.org/10.3748/wjg.v23.i20.3632.CrossRef

12.

Welch HG, Black WC. Overdiagnosis in Cancer. J Natl Cancer Inst. 2010;102(9):605–13. https://doi.org/10.1093/jnci/djq099.CrossRef

13.

Marcus, P. M.; Prorok, P. C.; Miller, A. B.; DeVoto, E. J.; Kramer, B. S. Conceptualizing Overdiagnosis in Cancer Screening. J. Natl. Cancer Inst. 2015, 107 (4). https://doi.org/10.1093/jnci/djv014.

14.

Mandel JS, et al. The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer. The New England Journal of Medicine. 2000;343(22):1603–7.CrossRef

15.

Koïvogui A, Balamou C, Rymzhanova R, et al. Colorectal Cancer Fecal Screening Test Completion after Age 74, Sources and Outcomes in French Program. World J Gastrointest Oncol. 2019;11(9):729–40. https://doi.org/10.4251/wjgo.v11.i9.729.CrossRef

16.

Lin OS, Kozarek RA, Schembre DB, et al. Screening Colonoscopy in Very Elderly Patients: Prevalence of Neoplasia and Estimated Impact on Life Expectancy. JAMA. 2006;295(20):2357–65. https://doi.org/10.1001/jama.295.20.2357.CrossRef

17.

Kistler CE. Long-Term Outcomes Following Positive Fecal Occult Blood Test Results in Older Adults: Benefits and Burdens. Arch Intern Med. 2011;171(15):1344. https://doi.org/10.1001/archinternmed.2011.206.CrossRef

18.

Lieberman D, Ladabaum U, Cruz-Correa M, et al. Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review. JAMA. 2016;316(20):2135. https://doi.org/10.1001/jama.2016.17418.CrossRef

19.

Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S. Colorectal Cancer in Saudi Arabia: Incidence, Survival, Demographics and Implications for National Policies. Ann Saudi Med. 2015;35(3):196–202. https://doi.org/10.5144/0256-4947.2015.196.CrossRef

20.

U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 2008, 149 (9), 627. https://doi.org/10.7326/0003-4819-149-9-200811040-00243.

21.

Aparicio T, Pamoukdjian F, Quero L, Manfredi S, Wind P, Paillaud E. Colorectal Cancer Care in Elderly Patients: Unsolved Issues. Dig Liver Dis. 2016;48(10):1112–8. https://doi.org/10.1016/j.dld.2016.05.011.CrossRef

22.

Quarini C, Gosney M. Review of the Evidence for a Colorectal Cancer Screening Programme in Elderly People. Age Ageing. 2009;38(5):503–8. https://doi.org/10.1093/ageing/afp103.CrossRef

23.

Ko CW, Sonnenberg A. Comparing Risks and Benefits of Colorectal Cancer Screening in Elderly Patients. Gastroenterology. 2005;129(4):1163–70. https://doi.org/10.1053/j.gastro.2005.07.027.CrossRef

24.

Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DSM. Adverse Events after Screening and Follow-up Colonoscopy. Cancer Causes Control CCC. 2012;23(2):289–96. https://doi.org/10.1007/s10552-011-9878-5.CrossRef

25.

Ko CW, Riffle S, Michaels L, et al. Serious Complications within 30 Days of Screening and Surveillance Colonoscopy Are Uncommon. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8(2):166–73. https://doi.org/10.1016/j.cgh.2009.10.007.CrossRef

26.

Day LW, Walter LC, Velayos F. Colorectal Cancer Screening and Surveillance in the Elderly Patient: Am. J Gastroenterol. 2011;106(7):1197–206. https://doi.org/10.1038/ajg.2011.128.CrossRef

27.

Wolf AMD, Fontham ETH, Church TR, et al. Colorectal Cancer Screening for Average-Risk Adults: 2018 Guideline Update from the American Cancer Society: ACS Colorectal Cancer Screening Guideline. CA Cancer J Clin. 2018;68(4):250–81. https://doi.org/10.3322/caac.21457.CrossRef

28.

Day LW, Velayos F. Colorectal Cancer Screening and Surveillance in the Elderly: Updates and Controversies. Gut Liver. 2015;9(2):143–51. https://doi.org/10.5009/gnl14302.CrossRef

29.

Ma W-T, Mahadeva S, Kunanayagam S, Poi PJ-H, Goh K-L. Colonoscopy in Elderly Asians: A Prospective Evaluation in Routine Clinical Practice. J Dig Dis. 2007;8(2):77–81. https://doi.org/10.1111/j.1443-9573.2007.00289.x.CrossRef

30.

Karajeh MA, Sanders DS, Hurlstone DP. Colonoscopy in Elderly People Is a Safe Procedure with a High Diagnostic Yield: A Prospective Comparative Study of 2000 Patients. Endoscopy. 2006;38(3):226–30. https://doi.org/10.1055/s-2005-921209.CrossRef

31.

Salzman B, Beldowski K, de la Paz A. Cancer Screening in Older Patients. Am Fam Physician. 2016;93(8):659–67.

32.

Warren, J. L.; Klabunde, C. N.; Mariotto, A. B. et al. Adverse Events after Outpatient Colonoscopy in the Medicare Population. Ann. Intern. Med. 2009, 150 (12), 849–857, W152. https://doi.org/10.7326/0003-4819-150-12-200906160-00008.

33.

García-Albéniz X, Hsu J, Bretthauer M, Hernán MA. Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study. Ann Intern Med. 2017;166(1):18. https://doi.org/10.7326/M16-0758.CrossRef

34.

García-Albéniz X, Hsu J, Bretthauer M, Hernán MA. Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years. Ann Intern Med. 2017;166(10):758–9. https://doi.org/10.7326/L17-0138.CrossRef

35.

Causada-Calo N, Bishay K, Albashir S, Al Mazroui A, Armstrong D. Association Between Age and Complications After Outpatient Colonoscopy. JAMA Netw Open. 2020;3(6):e208958. https://doi.org/10.1001/jamanetworkopen.2020.8958.CrossRef

36.

Ure T, Dehghan K, Vernava AM, Longo WE, Andrus CA, Daniel GL. Colonoscopy in the Elderly: Low Risk. High Yield Surg Endosc. 1995;9(5):505–8. https://doi.org/10.1007/BF00206836.CrossRef

37.

Yoong KKY. Colonoscopy in the Very Old: Why Bother? Postgrad Med J. 2005;81(953):196–7. https://doi.org/10.1136/pgmj.2004.023374.CrossRef

38.

Rabeneck L, Lewis JD, Paszat LF, Saskin R, Stukel TA. Risk of Proximal and Distal Colorectal Cancer Following Flexible Sigmoidoscopy: a population-based cohort study. Am J Gastroenterol. 2008;103(8):2075–82. https://doi.org/10.1111/j.1572-0241.2008.01932.x.CrossRef

39.

Zafar HM, Harhay MO, Yang J, Armstron K. Adverse Events Following Computed Tomographic Colonography Compared to Optical Colonoscopy in the Elderly. Prev Med Rep. 2014;1:3–8. https://doi.org/10.1016/j.pmedr.2014.08.001.CrossRef

40.

Pendsé DA, Taylor SA. Complications of CT Colonography: A Review. Eur J Radiol. 2013;82(8):1159–65. https://doi.org/10.1016/j.ejrad.2012.04.011.CrossRef

41.

Pickhardt PJ, Correale L, Delsanto S, Regge D, Hassan C. CT Colonography Performance for the Detection of Polyps and Cancer in Adults ≥ 65 Years Old: Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2018;211(1):40–51. https://doi.org/10.2214/AJR.18.19515.CrossRef

42.

Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659. https://doi.org/10.7326/0003-4819-149-9-200811040-00244.CrossRef

43.

van Hees F, Habbema JDF, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should Colorectal Cancer Screening Be Considered in Elderly Persons Without Previous Screening?: A Cost-Effectiveness Analysis. Ann Intern Med. 2014;160(11):750. https://doi.org/10.7326/M13-2263.CrossRef

44.

van Hees F, Saini SD, Lansdorp-Vogelaar I, et al. Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost Effectiveness. Gastroenterology. 2015;149(6):1425–37. https://doi.org/10.1053/j.gastro.2015.07.042.CrossRef

45.

Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA. 2016;315(23):2595. https://doi.org/10.1001/jama.2016.6828.CrossRef

46.

Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O’Brien S, Walter LC. Time Lag to Benefit after Screening for Breast and Colorectal Cancer: Meta-Analysis of Survival Data from the United States, Sweden, United Kingdom, and Denmark. BMJ. 2013;346:e8441. https://doi.org/10.1136/bmj.e8441.CrossRef

47.

Cenin, D. R.; Tinmouth, J.; Naber, S. K. et al. Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2020. https://doi.org/10.1016/j.cgh.2020.05.038.

48.

Lee SJ, Leipzig RM, Walter LC. Incorporating Lag Time to Benefit Into Prevention Decisions for Older Adults. JAMA. 2013;310(24):2609. https://doi.org/10.1001/jama.2013.282612.CrossRef

49.

Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular Trends in Colon and Rectal Cancer Relative Survival. J Natl Cancer Inst. 2013;105(23):1806–13. https://doi.org/10.1093/jnci/djt299.CrossRef

50.

Cho H, Klabunde CN, Yabroff KR, et al. Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies. Ann Intern Med. 2013;159(10):667–76. https://doi.org/10.7326/0003-4819-159-10-201311190-00005.CrossRef

51.

Wilt TJ, Harris RP, Qaseem A. High Value Care Task Force of the American College of Physicians. Screening for Cancer: Advice for High-Value Care from the American College of Physicians. Ann Intern Med. 2015;162(10):718–25. https://doi.org/10.7326/M14-2326.CrossRef

52.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, et al. Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Ann Intern Med. 2014;161(2):104. https://doi.org/10.7326/M13-2867.CrossRef

53.

Sonnenberg A. Cost-Effectiveness in the Prevention of Colorectal Cancer. Gastroenterol Clin North Am. 2002;31(4):1069–91. https://doi.org/10.1016/s0889-8553(02)00051-1.CrossRef

54.

Holt PR, Kozuch P, Mewar S. Colon Cancer and the Elderly: From Screening to Treatment in Management of GI Disease in the Elderly. Best Pract Res Clin Gastroenterol. 2009;23(6):889–907. https://doi.org/10.1016/j.bpg.2009.10.010.CrossRef

55.

Institut national du Cancer (INCa). [Medico-Economic Evaluation of Colorectal Cancer Screening / Technical Report, Decision Support]. April 2019.

56.

Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC. Cancer Screening Rates in Individuals With Different Life Expectancies. JAMA Intern Med. 2014;174(10):1558. https://doi.org/10.1001/jamainternmed.2014.3895.CrossRef

57.

Walter LC, Lindquist K, Nugent S, et al. Impact of Age and Comorbidity on Colorectal Cancer Screening among Older Veterans. Ann Intern Med. 2009;150(7):465–73. https://doi.org/10.7326/0003-4819-150-7-200904070-00006.CrossRef

58.

Tardieu, E.; Manfredi, S.; Cottet, V.; Faivre, J. Up to what age propose mass screening for colorectal cancer by faecal occult blood test? Analysis of a cohort in a well-defined population; Prague, Czech Republic, 2019; p s-0039–1681624. https://doi.org/10.1055/s-0039-1681624.

59.

Dodd RH, Kobayashi LC, von Wagner C. Perceived Life Expectancy and Colorectal Cancer Screening Intentions and Behaviour: A Population-Based UK Study. Prev Med Rep. 2019;16:101002. https://doi.org/10.1016/j.pmedr.2019.101002.CrossRef

60.

Wolf AMD, Schorling JB. Does Informed Consent Alter Elderly Patients’ Preferences for Colorectal Cancer Screening?: Results of a Randomized Trial. J Gen Intern Med. 2000;15(1):24–30. https://doi.org/10.1046/j.1525-1497.2000.01079.x.CrossRef

61.

Terret C, Castel-Kremer E, Albrand G, Droz JP. Effects of Comorbidity on Screening and Early Diagnosis of Cancer in Elderly People. Lancet Oncol. 2009;10(1):80–7. https://doi.org/10.1016/S1470-2045(08)70336-X.CrossRef

62.

Tinmouth J, Vella ET, Baxter NN, et al. Colorectal Cancer Screening in Average Risk Populations: Evidence Summary. Can J Gastroenterol Hepatol. 2016;2016:1–18. https://doi.org/10.1155/2016/2878149.CrossRef

63.

Salzman B, University TJ. Cancer Screening in Older Patients. Cancer Screen. 2016;93 (8):9.

64.

Nee J, Chippendale RZ, Feuerstein JD. Screening for Colon Cancer in Older Adults: Risks, Benefits, and When to Stop. Mayo Clin Proc. 2020;95(1):184–96. https://doi.org/10.1016/j.mayocp.2019.02.021.CrossRef

65.

Pasetto LM, Monfardini S. Colorectal Cancer Screening in Elderly Patients: When Should Be More Useful? Cancer Treat Rev. 2007;33(6):528–32. https://doi.org/10.1016/j.ctrv.2007.04.004.CrossRef

66.

Bénard F, Barkun AN, Martel M, von Renteln D. Systematic Review of Colorectal Cancer Screening Guidelines for Average-Risk Adults: Summarizing the Current Global Recommendations. World J Gastroenterol. 2018;24(1):124–38. https://doi.org/10.3748/wjg.v24.i1.124.CrossRef

67.

Altobelli E, D’Aloisio F, Angeletti PM. Colorectal Cancer Screening in Countries of European Council Outside of the EU-28. World J Gastroenterol. 2016;22(20):4946. https://doi.org/10.3748/wjg.v22.i20.4946.CrossRef

68.

Altobelli E, Rapacchietta L, Marziliano C, Campagna G, Profeta V, Fagnano R. Differences in Colorectal Cancer Surveillance Epidemiology and Screening in the WHO European Region. Oncol. Lett. 2018. https://doi.org/10.3892/ol.2018.9851.

69.

Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;315(23):2576. https://doi.org/10.1001/jama.2016.3332.CrossRef

70.

Canadian Task Force on Preventive Health Care. Recommendations on Screening for Colorectal Cancer in Primary Care. Can Med Assoc J. 2016;188(5):340–8. https://doi.org/10.1503/cmaj.151125.CrossRef

71.

Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. J Natl Compr Cancer Netw. 2018;16(8):939–49. https://doi.org/10.6004/jnccn.2018.0067.CrossRef

72.

Jung M. National Cancer Screening Programs and Evidence-Based Healthcare Policy in South Korea. Health Policy Amst Neth. 2015;119(1):26–32. https://doi.org/10.1016/j.healthpol.2014.08.012.CrossRef

73.

Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterolog. 2017;153(1):307–23. https://doi.org/10.1053/j.gastro.2017.05.013.CrossRef

74.

Sano Y, Byeon J-S, Li X-B, et al. Colorectal Cancer Screening of the General Population in East Asia. Dig Endosc Off J Jpn Gastroenterol Endosc Soc. 2016;28(3):243–9. https://doi.org/10.1111/den.12579.CrossRef

75.

Rolland Y, Benetos A, Gentric A, et al. Frailty in older population: a brief position paper from the French society of geriatrics and gerontology. Geriatr Psychol Neuropsychiatr Vieil. 2011;9(4):387–90. https://doi.org/10.1684/pnv.2011.0311.CrossRef

76.

Schonberg MA, Breslau ES, Hamel MB, Bellizzi KM, McCarthy EP. Colon Cancer Screening in U.S. Adults Aged 65 and Older According to Life Expectancy and Age. J Am Geriatr Soc. 2015;63(4):750–75. https://doi.org/10.1111/jgs.13335.CrossRef

77.

DuGoff EH, Canudas-Romo V, Buttorff C, Leff B, Anderson GF. Multiple Chronic Conditions and Life Expectancy: A Life Table Analysis. Med Care. 2014;52(8):688–94. https://doi.org/10.1097/MLR.0000000000000166.CrossRef

78.

Laditka JN, Laditka SB. Associations of Multiple Chronic Health Conditions with Active Life Expectancy in the United States. Disabil Rehabil. 2016;38(4):354–61. https://doi.org/10.3109/09638288.2015.1041614.CrossRef

79.

Maratt JK, Calderwood AH. Colorectal Cancer Screening and Surveillance Colonoscopy in Older Adults. Curr Treat Options Gastroenterol. 2019;17(2):292–302. https://doi.org/10.1007/s11938-019-00230-9.CrossRef

80.

Haute Autorité de Santé. [Post Polypectomy Surveillance Protocole]. 2013.

81.

Mongiat-Artus, P, Paillaud, E, Albrand G, Caillet P, Neuzillet Y. [Evaluation of the elderly patient with cancer]. Progres En Urol. J. Assoc. Francaise Urol. Soc. Francaise Urol. 2019, 29 (14), 807–827. https://doi.org/10.1016/j.purol.2019.08.279.

82.

Redín-Sagredo, M. J.; Aldaz Herce, P.; Casas Herrero, A.; Gutiérrez-Valencia, M.; Martínez-Velilla, N. [Heterogeneity amongst different diagnostic tools in frailty screening]. An. Sist. Sanit. Navar. 2019, 42 (2), 169–178. https://doi.org/10.23938/ASSN.0642.

83.

Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9. https://doi.org/10.1001/jama.1963.03060120024016.CrossRef

84.

Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. Gerontologist. 1969;9(3):179–86.CrossRef

85.

Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus Chronological Age: Geriatric Assessments to Guide Decision Making in Older Patients with Cancer. Lancet Oncol. 2018;19(6):e305–16. https://doi.org/10.1016/S1470-2045(18)30348-6.CrossRef

86.

Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic Indices for Older Adults: A Systematic Review. JAMA. 2012;307(2):182. https://doi.org/10.1001/jama.2011.1966.CrossRef

87.

Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External Validation of an Index to Predict Up to 9-Year Mortality of Community-Dwelling Adults Aged 65 and Older: EXTERNAL VALIDATION OF MORTALITY INDEX. J Am Geriatr Soc. 2011;59(8):1444–51. https://doi.org/10.1111/j.1532-5415.2011.03523.x.CrossRef

88.

Cruz M, Covinsky K, Widera EW, Stijacic-Cenzer I, Lee SJ. Predicting 10-Year Mortality for Older Adults. JAMA. 2013;309(9):874. https://doi.org/10.1001/jama.2013.1184.CrossRef

89.

Schoenborn NL, Boyd CM, Lee SJ, Cayea D, Pollack CE. Communicating About Stopping Cancer Screening: Comparing Clinicians’ and Older Adults’ Perspectives. Gerontologist. 2019;59(Supplement_1):S67–76. https://doi.org/10.1093/geront/gny172.CrossRef

90.

Pornet C, Denis B, Perrin P, Gendre I, Launoy G. Predictors of Adherence to Repeat Fecal Occult Blood Test in a Population-Based Colorectal Cancer Screening Program. Br J Cancer. 2014;111(11):2152–5. https://doi.org/10.1038/bjc.2014.507.CrossRef

91.

Sheinfeld Gorin S, Gauthier J, Hay J, Miles A, Wardle J. Cancer Screening and Aging: Research Barriers and Opportunities. Cancer. 2008;113(12 Suppl):3493–504. https://doi.org/10.1002/cncr.23938.CrossRef

92.

Lewis CL, Golin CE, DeLeon C, et al. A Targeted Decision Aid for the Elderly to Decide Whether to Undergo Colorectal Cancer Screening: Development and Results of an Uncontrolled Trial. BMC Med Inform Decis Mak. 2010;10:54. https://doi.org/10.1186/1472-6947-10-54.CrossRef

93.

Pornet C, Dejardin O, Morlais F, Bouvier V, Launoy G. Socioeconomic Determinants for Compliance to Colorectal Cancer Screening. A Multilevel Analysis. J Epidemiol Community Health. 2010;64(4):318–24. https://doi.org/10.1136/jech.2008.081117.CrossRef

Title: Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD)
Authors: Lydia Guittet
Valérie Quipourt
Thomas Aparicio
Elisabeth Carola
Jean-François Seitz
Elena Paillaud
Astrid Lievre
Rabia Boulahssass
Carole Vitellius
Leila Bengrine
Florence Canoui-Poitrine
Sylvain Manfredi
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Colonoscopy
Colorectal Cancer
Colorectal Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-022-10418-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

IRB

Please log in to get access to this content

Other articles of this Issue 1/2023

Identification of a Novel CD8+ T cell exhaustion-related gene signature for predicting survival in hepatocellular carcinoma

Retraction Note: MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma

Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol

Keynote webinar | Spotlight on antibody–drug conjugates in cancer